2005
DOI: 10.1021/jm050100l
|View full text |Cite
|
Sign up to set email alerts
|

Design, Synthesis, and Biological Evaluation of Sirtinol Analogues as Class III Histone/Protein Deacetylase (Sirtuin) Inhibitors

Abstract: In a search for potent inhibitors of class III histone/protein deacetylases (sirtuins), a series of sirtinol analogues have been synthesized and the degree of inhibition was assessed in vitro using recombinant yeast Sir2, human SIRT1, and human SIRT2 and in vivo with a yeast phenotypic assay. Two analogues, namely, 3- and 4-[(2-hydroxy-1-naphthalenylmethylene)amino]-N-(1-phenylethyl)benzamide (i.e., m- and p-sirtinol), were 2- to 10-fold more potent than sirtinol against human SIRT1 and SIRT2 enzymes. In yeast… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

7
115
0
2

Year Published

2006
2006
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 162 publications
(124 citation statements)
references
References 62 publications
7
115
0
2
Order By: Relevance
“…The IC 50 of sirtinol to SIRT1 in the assay using the p53 peptide was 120.2 μM (Table 2). This result is consistent with the previous data (131 μM) from a different fluorimetric assay (26). On the other hand, the IC 50 of compound 17 against SIRT1 was 40.3 μM and lower than that of sirtinol.…”
Section: Discussionsupporting
confidence: 93%
“…The IC 50 of sirtinol to SIRT1 in the assay using the p53 peptide was 120.2 μM (Table 2). This result is consistent with the previous data (131 μM) from a different fluorimetric assay (26). On the other hand, the IC 50 of compound 17 against SIRT1 was 40.3 μM and lower than that of sirtinol.…”
Section: Discussionsupporting
confidence: 93%
“…Small molecule inhibitors of the SIRT1 deacetylase have been proposed as novel anticancer agents [22][23][24] , presumably through activating the apoptotic response in cancer cells. On the other hand, activation of SIRT1 in mice also protects them against dietinduced obesity and insulin resistance, mainly through regulating metabolic pathways 25,26 .…”
mentioning
confidence: 99%
“…Physiological studies, target confirmation, and drug development have been hampered, however, by shortcomings of available Sirtuin inhibitors, which mostly show limited potency and/or isoform specificity and exploit unknown binding sites and mechanisms (21,22). The widely used inhibitor sirtinol, for example, has an IC 50 of 38 μM against Sirt2 and no effect on Sirt5, inhibits Sirt1 only approximately threefold weaker, and its effect on other isoforms and its mechanism are unknown (23)(24)(25). Ex-527 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; Fig.…”
mentioning
confidence: 99%